[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cardiovascular Drugs: Market Research Report

April 2010 | 1058 pages | ID: CFB1E5C4820EN
Global Industry Analysts, Inc

US$ 4,450.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million.

Cardiovascular diseases can be prevented or treated using different classes of drugs.

Broadly, the major classes of cardiovascular drugs include: ACE Inhibitors, Angiotensin II Receptor Blockers, Antiarrhythmics, Antithrombotics, Beta Blockers,. Calcium Channel Blockers, Antihyperlipidemics, and Others.

The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 115 companies including many key and niche players such as Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Biovail Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Forest Laboratories, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, and The Medicines Company.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
36


More Publications